A Single-centre, Randomized, Double-blind, Dose-ascending, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral TID Doses (One Day) of GSK2982772 in Japanese Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Autoimmune disorders; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 25 Jan 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2018 Status changed from not yet recruiting to recruiting.